뇌질환의 혁신, 뉴로벤티(NeuroVenti)

NEWS

Here's the news about NeuroVenti

[2022 first half of 2022 Excellent Patent Award] Development of a cure…

페이지 정보

조회 479회 작성일 22-07-26

본문

[2022 first half of 2022 Excellent Patent Award] Development of a cure for brain diseases such as autism

22-07-26


[2022 first half excellent patent award] Neuroventi

 

Neuroventi (CEO Shin Chan-young) is a global brain-specialized bio-venture that leads the ‘integrated treatment platform for brain development disorders and intractable brain diseases’. It has a business portfolio covering various neurological diseases such as autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), schizophrenia, depression, and Parkinson's disease, and provides R&D and non-clinical CDRO services.


The main business areas are ▲ new drug development ▲ brain disease treatment CRO and CDO service ▲ integrated treatment platform provision. CEO Chan-Young Shin and research personnel are first-generation researchers in the basic field of autism in Korea, and are striving to develop a cure.


Brain diseases such as autism require more sophisticated control than other diseases because multiple targets work in a complex way. Neuroventi has developed complex target precision control technology based on optimal pharmacological selectivity, and through this, is attempting clinical trials for brain diseases for which there is no cure, receiving a lot of attention at home and abroad.


Neuroventi has succeeded in developing a first-in-disease medicine, and is dreaming of becoming a company that spreads the pride of K-Bio to the world and gives hope to people suffering from incurable brain diseases such as autism.1